Sarepta Therapeutics (NASDAQ:SRPT) Price Target Increased to $235.00 by Analysts at Needham & Company LLC

Sarepta Therapeutics (NASDAQ:SRPT) had its price target lifted by Needham & Company LLC from $166.00 to $235.00 in a research note published on Friday, Benzinga reports. The firm currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also recently weighed in on SRPT. TheStreet raised shares of Sarepta Therapeutics from a d rating to a c- rating in a research note on Monday, March 4th. Bank of America upped their price target on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a buy rating in a research note on Friday. Citigroup upped their price target on shares of Sarepta Therapeutics from $160.00 to $172.00 and gave the stock a buy rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. lowered their price objective on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an overweight rating on the stock in a research note on Friday, May 3rd. Finally, Mizuho increased their price objective on shares of Sarepta Therapeutics from $145.00 to $179.00 and gave the company a buy rating in a research note on Friday, May 17th. Four investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $184.83.

Sarepta Therapeutics Stock Up 1.9 %

Shares of Sarepta Therapeutics stock opened at $163.85 on Friday. The company has a market cap of $15.49 billion, a P/E ratio of 1,489.55 and a beta of 0.96. The company has a debt-to-equity ratio of 1.18, a quick ratio of 3.44 and a current ratio of 4.05. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $173.25. The firm has a fifty day moving average of $126.47 and a two-hundred day moving average of $120.71.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The business had revenue of $413.50 million for the quarter, compared to analysts’ expectations of $375.52 million. During the same period in the prior year, the company posted ($1.44) EPS. The business’s revenue for the quarter was up 63.1% on a year-over-year basis. On average, analysts forecast that Sarepta Therapeutics will post 2.99 earnings per share for the current year.

Insider Transactions at Sarepta Therapeutics

In other news, insider Dallan Murray sold 3,635 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total transaction of $508,900.00. Following the transaction, the insider now directly owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 7.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Principal Securities Inc. purchased a new position in shares of Sarepta Therapeutics during the 4th quarter worth about $26,000. Mather Group LLC. purchased a new position in Sarepta Therapeutics in the first quarter valued at approximately $28,000. Riggs Asset Managment Co. Inc. raised its holdings in Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 125 shares during the period. Cary Street Partners Investment Advisory LLC raised its holdings in Sarepta Therapeutics by 154.0% in the third quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 154 shares during the period. Finally, New Covenant Trust Company N.A. purchased a new position in Sarepta Therapeutics in the first quarter valued at approximately $32,000. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.